The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Very good point. I also wonder if current antibody testing are detecting the right things, because if antibodies drop off but no second infection maybe we are missing the thing that offers protection
https://www.businessinsider.com/coronavirus-antibodies-study-herd-immunity-unachievable-spain-2020-7
The mosaic machine is a blood assay machine for all types of blood analysis, quotient just added covid antibody testing to the long list of test capabilities. the kit was designed for general blood labs to replace slower throughput kit.
DF did not confirm the really important differentiating feature of this test that Will make it a blockbuster. Namely, that it is highly accurate when used by Joe public jabbing their own fingers at home? Until that case is proven then there is still a lot of risk, at least from the RTC income stream
DF did not confirm the really important differentiating feature of this test that Will make it a blockbuster. Namely, that it is highly accurate when used by Joe public jabbing their own fingers at home? Until that case is proven then there is still a lot of risk, at least from the RTC income stream
I'm actually a teacher in a school, but where do I go to get paid to deramp?
"Testing (of omega device) complete by the end of August". What will happen to the SP between now and end of August?
...
Sneak the price up a bit to encourage people to buy into the rise and use it to offload more MM stock
Hopefully the track will change to rocket man soon
About 55m shares of volume since 10th June. Is that enough to off load the 38m Acacia shares? I think Acacia bought for about 6p sold to MM for 10p and they have been clearing them between 11 and 12p slowly so they don't drop the SP too much
The 25m Acacia shares disappeared with no TR1. Could it be that the MM took them and has been clearing them through the market? Would explain the SP being down for so long
We only own 49% so ORPH shareholders only get half the sale value so £50m divided by 664m is 7.5p per share dividend
Still filing patients for flu in late 2019
Interesting reading of patients lodged by PepTcell related to Imutex work https://patents.justia.com/assignee/peptcell-limited
Surely that's a buy of the New shares showing as a sell because the price is below the mid of the ask and bid
Seems to be cured now, back to it's usual colour ??
It's hypothermia, quick dump all your shares now before you get frozen out of your account
Presentation mentioned 1m Tests per week, priced at £10 but surely the Oxford guys who developed the test Will get the lions share of profits leaving maybe £1-2 per test profits for ODX so only £52-104 m profits from Tests,still very good and if mcap was 3x still a long way for SP to Go
Can you point me to the research on the reliability of patient-administered POC lateral flow blood tests, as opposed to clinician-administered POC tests
perhaps this is why design freeze is taking so long, can't get better results than already available tests, and certainly can't do it with patient-administered POC test due to unreliability of joe public doing it, meanwhile, others are launching their products to market